Implications of the changing face of Clostridium difficile disease for health care practitioners

被引:75
作者
McFarland, Lynne V.
Beneda, Henry W.
Clarridge, Jill E.
Raugi, Gregory J.
机构
[1] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA
[2] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[3] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[4] VA Puget Sound Hlth Care Syst, Dept Infect Control, Seattle, WA 98101 USA
[5] VA Puget Sound Hlth Care Syst, Lab Serv, Seattle, WA 98101 USA
[6] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[7] Vet Adm Puget Sound Hlth Care Syst, Dermatol Sect, Primary & Specialty Serv, Seattle, WA USA
[8] Univ Washington, Div Dermatol, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1016/j.ajic.2006.06.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Recent reported outbreaks of Clostridium difficile-associated disease in Canada have changed the profile of C difficile infections. Historically C difficile disease was thought of mainly as a nosocomial disease associated with broad-spectrum antibiotics, and the disease was usually riot life threatening. The ernergence of an epidemic strain, BI/NAPI/027, which produces a binary toxin in addition to the 2 classic C difficile toxins A and B and is resistant to some fluoroquinolones, was associated with large numbers of cases with high rates of mortality Recently, C difficile has been reported more frequently in non hospital-based settings, such as community-acquired cases. The C difficile disease is also being reported in populations once considered of low risk (children and young healthy women). In addition, poor response to metronidazole treatment is increasing, Faced with an increasing incidence of C difficile infections and the changing profile of patients who become infected, this paper will reexamine the current concepts on the epidemiology and treatment of C difficile-associated disease, present new hypotheses for risk factors, examine the role of spores in the transmission of C difficile, and provide recommendations that may enhance infection control practices.
引用
收藏
页码:237 / 253
页数:17
相关论文
共 171 条
  • [1] Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Aboudola, S
    Kotloff, KL
    Kyne, L
    Warny, M
    Kelly, EC
    Sougioultzis, S
    Giannasca, PJ
    Monath, TP
    Kelly, CP
    [J]. INFECTION AND IMMUNITY, 2003, 71 (03) : 1608 - 1610
  • [2] Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA
    Ackermann, G
    Tang, YJ
    Kueper, R
    Heisig, P
    Rodloff, AC
    Silva, J
    Cohen, SH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) : 2348 - 2353
  • [3] Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in north India
    Agarwal, Ritesh
    Gupta, Dheeraj
    Ray, Pallab
    Aggarwal, Ashutosh N.
    Jindal, Surinder K.
    [J]. JOURNAL OF INFECTION, 2006, 53 (02) : 98 - 105
  • [4] Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates
    Åkerlund, T
    Svenungsson, B
    Lagergren, Å
    Burman, LG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) : 353 - 358
  • [5] Al-Eidan FA, 2000, J CLIN PHARM THER, V25, P101
  • [6] Al-Tureihi Farrah Ibrahim J, 2005, J Am Med Dir Assoc, V6, P105, DOI 10.1016/j.jamda.2005.01.003
  • [7] Toxigenic status of Clostridium difficile in a large Spanish teaching hospital
    Alonso, R
    Martín, A
    Peláez, T
    Marín, M
    Rodríguez-Creixéms, M
    Bouza, E
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (02) : 159 - 162
  • [8] Clostridium difficile-associated diarrhea:: Predictors of severity in patients presenting to the emergency department
    Andrews, CN
    Raboud, J
    Kassen, BO
    Enns, R
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 2003, 17 (06): : 369 - 373
  • [9] Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile
    Apisarnthanarak, A
    Zack, JE
    Mayfield, JL
    Freeman, J
    Dunne, WM
    Little, JR
    Mundy, LM
    Fraser, VJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) : 601 - 602
  • [10] Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001
    Archibald, LK
    Banerjee, SN
    Jarvis, WR
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) : 1585 - 1589